急性髓性白血病:2025年关于诊断,风险分层和管理的更新
Shai Shimony1, Maximilian Stahl1, Richard M Stone1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
由于新的治疗方法和洞察力,急性髓性白血病 (AML) 管理已取得显著进展. 个性化风险评估和可测量的残留疾病 (MRD) 的监测对于最佳的治疗策略至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 急性髓性白血病 (AML) 是一种致命的骨髓癌,治疗风景不断变化.
- 近年来,由于对AML的理解和技术的提高,AML诊断,风险评估,监测和治疗发生了巨大的变化.
研究的目的:
- 总结AML管理的现状,包括诊断,风险分层和治疗方法.
- 突出新生物学见解和技术进步对AML护理的影响.
主要方法:
- 诊断依赖于在血液或骨髓中识别不成熟的白血病细胞.
- 风险分类整合了细胞遗传和分子发现,预后因素因治疗方法而异.
- 可测量的残留疾病 (MRD) 量化越来越多地用于响应评估和监测.
主要成果:
- 至少有12种新的治疗方法已被批准用于AML.
- 新药在治疗算法中的最佳整合正在积极辩论中.
- 治疗策略越来越多地纳入患者的目标,并发症和疾病特征.
结论:
- 最近的进展对AML的管理产生了重大影响.
- 个性化风险评估和动态MRD监测是现代AML治疗的关键组成部分.
- 整合新的药物和以患者为中心的因素对于优化AML治疗策略至关重要.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
08:00A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016
相关概念视频
Differentiation of Common Myeloid Progenitor Cells
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Lineage Commitment
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
